Article Text

Download PDFPDF

18 Downstream investigation of non-cardiac incidental findings in patients undergoing ct coronary angiography: findings from the multi-centre randomised controlled scot-heart trial
  1. Michelle C Williams1,
  2. Amanda Hunter1,
  3. Anoop Shah1,
  4. John Dreisbach2,
  5. Jonathan Weir McCaull3,
  6. Mark Macmillan4,
  7. Rachel Kirkbride4,
  8. Andrew Baird4,
  9. Fiona Hawke5,
  10. Saeed Mirsadraee6,
  11. Edwin van Beek6,
  12. David E Newby1,
  13. Giles Roditi2
  1. 1University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, Edinburgh, UK
  2. 2Department of Radiology, Glasgow Royal Infirmary, Glasgow, UK
  3. 3Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
  4. 4Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, UK
  5. 5Department of Radiology, Borders General Hospital, Melrose, UK
  6. 6Clinical Research Imaging Centre, University of Edinburgh, Edinburgh, UK


Introduction Non-cardiac findings can be identified on computed tomography coronary angiography (CTCA). We assess the follow-up of non-cardiac incidental findings, and impact of changes in lung nodule follow-up guidelines.

Methods This sub-study of the SCOT-HEART randomised controlled trial assessed images and health records of patients who underwent CTCA. Non-cardiac incidental findings were classified as the cause of symptoms (yes, probable, unlikely, no) and significant findings were those requiring further investigation, follow-up or treatment. Recommendations for lung nodule follow-up were provided as per 2005 Fleischner guidelines. We assessed potential changes using the 2015 British Thoracic Society (BTS) guidelines and 2017 Fleischner guidelines.

Results CTCA was performed in 1778 patients and non-cardiac findings were identified in 677 (38%). 173 (10%) were defined as significant and 22 (1.2%) were the cause of symptoms. Lung nodules, masses or granuloma were identified in 200 (11%). Follow-up imaging for lung nodules was recommended for 126 patients (7%) but performed in 85 (4.7%). Malignancy was subsequently diagnosed in 7 (0.4%). Using 2016 BTS guidelines would mean 68 fewer scans in 47 patients and the 2017 Fleischner guidelines would mean 78 fewer scan in 53 patients. None of these developed malignancy. Applying the 2016 BTS guidelines would mean a 50% cost saving and the 2017 Fleischner guidelines would mean a 57% cost saving.

Conclusion Significant non-cardiac findings are uncommon, but may represent an important treatable cause of chest pain. New guidelines for lung nodule follow-up will reduce the number CT scans required, without the risk of missing malignancy.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.